The first moments in a newborn’s life mark the beginning of a journey filled with hope, yet they may also bring certain health challenges that require awareness, care, and attention. One of these challenges is Neonatal Abstinence Syndrome (NAS), a condition that may occur in some newborns following exposure to certain medications or substances during pregnancy, when the supply of these substances is discontinued after birth. This condition may affect the baby’s comfort, ability to feed, sleep patterns, and adjustment to life outside the womb.At Dalili Medical, we recognize the importance of understanding this syndrome, including its causes, symptoms, prevention strategies, and appropriate management approaches. We also emphasize the essential role of families and healthcare professionals in providing compassionate and effective care. Every baby deserves a safe beginning, and every mother deserves support without blame or judgment. Health awareness is the first step toward protecting our little ones and giving them a better chance to grow, recover, and thrive.

1. What is Neonatal Abstinence Syndrome (NAS)?

Neonatal Abstinence Syndrome is a group of symptoms that may occur in newborns following exposure to certain medications or substances during pregnancy, particularly opioids, when the supply of these substances is discontinued after birth.

2. When do symptoms of Neonatal Abstinence Syndrome begin?

The timing of symptom onset varies depending on the type of substance and its effects on the body. Symptoms may begin within the first 24–72 hours after birth, while in some cases, they may appear several days later, particularly following exposure to long-acting substances such as methadone.

3. Does every newborn exposed to certain substances during pregnancy develop Neonatal Abstinence Syndrome?

No. Not all newborns exposed to these substances during pregnancy develop withdrawal symptoms. The likelihood and severity of symptoms vary according to several factors, including the type of substance, dosage, duration of exposure, and exposure to other medications or substances.

4. How long does treatment for Neonatal Abstinence Syndrome take?

The duration of treatment varies from one newborn to another, depending on symptom severity, the type of substance involved, and the infant’s response to treatment. Mild cases may improve within several days, while more severe cases may require medical monitoring and treatment for several weeks.

5. Is breastfeeding safe for infants with Neonatal Abstinence Syndrome?

Breastfeeding may help soothe the infant and strengthen the bond between mother and baby. However, its safety depends on the type of medication or substance the mother uses, the dosage, the mother’s health and stability, and the infant’s condition. Mothers should consult a healthcare professional to determine whether breastfeeding is appropriate. Prescribed medications should not be discontinued or their dosages changed without medical supervision.

6. Can Neonatal Abstinence Syndrome affect a child’s future development?

The long-term effects of NAS cannot be determined by the diagnosis alone. Outcomes may be influenced by several factors, including prematurity, exposure to multiple substances during pregnancy, family and environmental circumstances, and access to appropriate healthcare. Regular medical follow-up helps monitor the child’s growth and development and identify any potential developmental delays at an early stage.

7. What is the difference between Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS)?

NAS is a general term for neonatal withdrawal symptoms that may be associated with exposure to various medications and substances during pregnancy. NOWS is a more specific term used to describe withdrawal symptoms in newborns resulting from opioid exposure during pregnancy.

8. What are the main assessment tools used to evaluate Neonatal Abstinence Syndrome?

The Finnegan Neonatal Abstinence Scoring System is one of the tools used to assess withdrawal symptoms in newborns and determine their severity. Another approach is Eat, Sleep, Console (ESC), which focuses on the infant’s ability to feed, sleep, and be consoled. The choice of assessment method depends on the infant’s clinical condition and the protocol adopted by the healthcare facility.

Types of Neonatal Abstinence Syndrome (NAS)

Neonatal Abstinence Syndrome can be classified according to the substance the fetus was exposed to during pregnancy or according to the nature and timing of the symptoms that appear after birth.

First: Types According to the Causative Substance

1. Opioid-Related NAS

This condition occurs when a fetus is exposed to opioids during pregnancy and the supply of these substances is discontinued after birth. Examples include heroin, methadone, buprenorphine, morphine, and fentanyl.

Common symptoms include tremors, high-pitched crying, irritability, feeding difficulties, vomiting, and diarrhea.

2. Sedative-Related Withdrawal

This condition may occur following fetal exposure to certain sedative medications during pregnancy, such as benzodiazepines and barbiturates.

Possible symptoms include irritability, sleep disturbances, tremors, increased muscle tone, and, in severe cases, seizures.

3. Poor Neonatal Adaptation Syndrome Associated with Antidepressant Exposure

Some newborns exposed to antidepressants during pregnancy, particularly selective serotonin reuptake inhibitors (SSRIs), may develop symptoms of poor neonatal adaptation.

Possible symptoms include tremors, irritability, feeding difficulties, respiratory disturbances, and changes in muscle tone. This condition is commonly known as Poor Neonatal Adaptation Syndrome and does not necessarily represent true withdrawal.

4. Symptoms Associated with Alcohol Exposure

Prenatal alcohol exposure may cause neurological and developmental problems. Withdrawal-like symptoms may occur in some newborns, although they are less common.

These symptoms should be distinguished from Fetal Alcohol Syndrome, which is associated with the effects of alcohol on fetal growth and development.

5. Symptoms Associated with Nicotine and Stimulant Exposure

Fetal exposure to nicotine or stimulants, such as amphetamines and cocaine, may be associated with symptoms after birth, including irritability, sleep disturbances, and feeding difficulties.

However, these substances do not necessarily cause a traditional neonatal withdrawal syndrome. The symptoms may instead result from the effects of the substances on the fetus or from difficulties with postnatal adaptation.

Second: Classification According to Symptom Onset

- Early onset: Symptoms begin within the first hours or days after birth. In cases involving certain short-acting opioids, symptoms often appear within 24–72 hours.

- Delayed onset: Symptoms may begin several days after birth, particularly following exposure to long-acting substances such as methadone. The timing varies according to the substance involved and the circumstances of exposure.

Causes of Neonatal Abstinence Syndrome (NAS)

Neonatal Abstinence Syndrome most commonly occurs following fetal exposure to certain medications or substances that affect the nervous system during pregnancy, followed by the discontinuation of exposure after birth. This may result in withdrawal symptoms or difficulties with postnatal adaptation.

The likelihood and severity of symptoms vary according to the type of substance, the duration of exposure, and other maternal and infant factors.

First: Main Causes of Neonatal Abstinence Syndrome

1. Opioid Exposure During Pregnancy

Exposure to opioids is one of the major causes of neonatal withdrawal. Examples include:

• Heroin

• Methadone

• Buprenorphine

• Morphine and fentanyl

Physical dependence may develop in the fetus following exposure to these substances. After birth, the interruption of their transfer through the placenta may lead to withdrawal symptoms in the newborn.

2. Use of Certain Sedative Medications

Exposure to medications that affect the central nervous system, such as benzodiazepines and barbiturates, may be associated with withdrawal symptoms in newborns, particularly when these medications are used regularly throughout pregnancy.

1. 3. Exposure to Antidepressants and Certain Psychiatric Medications

   Some newborns may develop symptoms of poor neonatal adaptation following exposure to certain antidepressants during pregnancy, such as selective serotonin reuptake inhibitors (SSRIs). These symptoms do not necessarily represent neonatal withdrawal syndrome in the strict clinical sense.

   4. Exposure to Alcohol, Nicotine, and Stimulants

   Exposure to alcohol, nicotine, cocaine, and amphetamines during pregnancy may affect fetal health and the newborn’s ability to adapt after birth. The nature of these effects varies, as not all these substances cause a traditional neonatal withdrawal syndrome.

   Second: Factors That May Increase the Likelihood or Severity of Symptoms

   • Duration of exposure: Continued exposure throughout pregnancy may influence the likelihood of symptoms developing.

   • Type of substance and duration of action: The onset and duration of symptoms vary according to the pharmacological properties of the substance.

   • Exposure to multiple substances: Using several medications or substances together may complicate symptoms and their assessment.

   • The newborn’s health status: Prematurity and certain medical conditions may influence the nature of symptoms and their evaluation.

   • Individual differences: Symptoms do not occur with the same severity in all newborns, even when they are exposed to the same substance.

   Symptoms of Neonatal Abstinence Syndrome (NAS)

   Neonatal Abstinence Syndrome (NAS) is a group of symptoms and clinical signs that may occur in newborns when the supply of certain medications or substances to which they were exposed during pregnancy is discontinued, particularly opioids. The severity and timing of symptoms vary according to the type of substance and its duration of action. Symptoms may begin within the first hours after birth or may be delayed for several days.

   First: Main Symptoms and Clinical Signs

   1. Neurological Symptoms

   • Severe irritability and increased sensitivity to stimuli.

   • Persistent, high-pitched crying.

   • Tremors or shaking.

   • Increased muscle tone (hypertonia).

   • Sleep disturbances and difficulty settling.

   • Exaggerated reflexes (hyperactive reflexes).

   • Seizures, which are rare and generally associated with severe cases.

   2. Gastrointestinal Symptoms

   • Feeding difficulties and reduced ability to feed effectively.

   • A weak or ineffective sucking reflex.

   • Vomiting.

   • Diarrhea.

   • Poor weight gain or weight loss.

   • Dehydration due to fluid loss in severe cases.

   3. Respiratory Symptoms

   • Rapid breathing (tachypnea).

   • Nasal congestion and frequent sneezing.

   • Increased work of breathing in some cases.

   • Respiratory disturbances requiring medical evaluation.

   4. Autonomic Nervous System Symptoms

   • Excessive sweating.

   • Elevated body temperature.

   • Frequent yawning.

   • Nasal congestion.

   • Skin mottling or intermittent changes in skin color.

   Second: When Do Symptoms Appear?

   Symptoms commonly develop within the first 24–72 hours after birth. However, the timing varies depending on the substance involved. Symptoms may be delayed for several days following exposure to certain long-acting substances, such as methadone.

   Complications of Neonatal Abstinence Syndrome (NAS)

   The complications of Neonatal Abstinence Syndrome (NAS) include a range of health problems that may affect newborns following the discontinuation of exposure to certain substances, particularly opioids, to which they were exposed during pregnancy. The severity of complications varies from one infant to another, depending on the type of substance, duration of exposure, severity of symptoms, and the newborn’s overall health.

   First: Short-Term Complications

   1. Neurological Disturbances

   • Tremors and severe irritability.

   • Persistent crying and difficulty soothing the infant.

   • Sleep disturbances.

   • Increased muscle tone.

   • Seizures in severe cases, although these are less common.

    

2. 2. Feeding and Gastrointestinal Problems

   • Difficulty breastfeeding or bottle-feeding, with weak sucking and swallowing.

   • Vomiting and diarrhea.

   • Weight loss or poor weight gain.

   • Dehydration due to fluid loss and inadequate nutritional intake.

   3. Respiratory Problems

   • Rapid breathing.

   • Respiratory disturbances in some infants.

   • The need for intensive medical monitoring or respiratory support in certain cases, depending on the infant’s clinical condition.

   4. Disturbances in Vital Functions

   • Elevated body temperature.

   • Excessive sweating.

   • Changes in heart rate in some cases.

   • Difficulty regulating sleep and achieving a calm state.

   Second: Potential Long-Term Complications

   Some children exposed to substances that affect the nervous system during pregnancy may face an increased risk of certain developmental and behavioral difficulties, including:

   • Delays in certain aspects of growth and motor development.

   • Attention and learning difficulties.

   • Behavioral or emotional problems.

   • Difficulties with language development and cognitive abilities.

   Important note: These complications do not occur in all children diagnosed with Neonatal Abstinence Syndrome, and they cannot be attributed to the syndrome alone. Outcomes may also be influenced by factors such as prematurity, maternal health, exposure to multiple substances during pregnancy, family and environmental circumstances, and access to appropriate healthcare.

   Third: Complications That May Require Hospitalization

   Some cases may require hospitalization for monitoring and treatment, particularly when any of the following conditions occur:

   • Inability to feed adequately.

   • Dehydration or significant weight loss.

   • Seizures.

   • Difficulty breathing.

   • Severe symptoms requiring pharmacological treatment under medical supervision.

   Fourth: Can Neonatal Abstinence Syndrome Lead to Death?

   Death is not the usual outcome of Neonatal Abstinence Syndrome. However, a newborn’s life may be at risk if serious complications develop or other underlying medical conditions are present.

   Therefore, early diagnosis, appropriate medical monitoring, and timely therapeutic intervention when necessary are important factors in reducing complications and improving health outcomes.

   Fifth: How Can Complications Be Minimized?

   • Early diagnosis and monitoring of symptoms after birth.

   • Providing a calm environment suitable for the infant’s rest and sleep.

   • Ensuring adequate nutrition and monitoring weight and fluid intake.

   • Administering medication when necessary, based on the physician’s assessment.

   • Monitoring the child’s growth and development after hospital discharge.

   • Providing psychological and healthcare support for the mother and family.

   Diagnosis of Neonatal Abstinence Syndrome (NAS)

   The diagnosis of Neonatal Abstinence Syndrome (NAS) relies on gathering information about medication and substance exposure during pregnancy, evaluating clinical symptoms and signs in the newborn, using appropriate assessment tools, and ruling out other medical conditions that may present with symptoms similar to withdrawal.

   First: Maternal History

   The physician gathers information about the pregnancy and any medications or substances the mother may have been exposed to, including:

   • Use of opioids, such as methadone, heroin, and buprenorphine.

   • Use of sedatives or certain psychiatric medications during pregnancy.

   • The type of substance used, duration of use, and timing of the last dose.

   • Exposure to more than one substance at the same time.

   • A previous history of giving birth to an infant with Neonatal Abstinence Syndrome.

   Second: Clinical Examination

   The physician performs a comprehensive examination of the newborn to identify signs that may indicate the syndrome, including:

   • Neurological symptoms: Tremors, irritability, high-pitched crying, and increased muscle tone.

   • Gastrointestinal symptoms: Poor feeding, vomiting, and diarrhea.

   • Respiratory symptoms: Rapid or irregular breathing.

   • Autonomic nervous system symptoms: Excessive sweating, yawning, frequent sneezing, and elevated body temperature.

   Third: Symptom Assessment Tools

   1. Finnegan Neonatal Abstinence Scoring System

   This scoring system is used to assess neonatal withdrawal symptoms repeatedly by monitoring signs such as tremors, crying, sleep disturbances, and feeding difficulties. The results are interpreted according to the healthcare facility’s established protocol to determine whether therapeutic intervention is necessary.

   2. Eat, Sleep, Console (ESC) Approach

   This approach evaluates the newborn’s ability to perform three essential functions:

   • Eat: The infant’s ability to feed effectively.

   • Sleep: The infant’s ability to sleep for an appropriate period.

   • Console: The infant’s ability to be soothed within a reasonable amount of time with the help of a caregiver.

   This approach helps guide individualized care and may reduce the need for pharmacological treatment in some newborns.

   Fourth: Laboratory Investigations

   There is no single laboratory test that confirms Neonatal Abstinence Syndrome in every case. However, physicians may order certain investigations when necessary, including:

   • Newborn urine testing: Used to detect certain substances or their metabolites, generally reflecting relatively recent exposure.

   • Meconium testing: May help identify exposure to certain substances over a longer period during pregnancy.

   • Umbilical cord tissue testing: Can be used to detect prenatal exposure to certain substances.

   • Blood tests: These may include blood glucose and electrolyte measurements to assess complications and rule out other causes of symptoms.

   The accuracy of these tests depends on the substance involved, the timing of exposure, and the method of specimen collection. Therefore, a negative result does not necessarily rule out prior exposure.

    

3. Fifth: Differential Diagnosis

   Certain medical conditions that may present with symptoms similar to Neonatal Abstinence Syndrome must be ruled out, including:

   • Hypoglycemia (low blood glucose).

   • Neonatal sepsis.

   • Hypocalcemia (low blood calcium levels).

   • Certain neurological disorders.

   • Respiratory and feeding disorders.

   Pharmacological Treatment of Neonatal Abstinence Syndrome (NAS)

   The treatment of Neonatal Abstinence Syndrome (NAS) depends on the severity of symptoms, the type of substance the fetus was exposed to during pregnancy, and the newborn’s overall health. Treatment aims to relieve withdrawal symptoms, improve the infant’s ability to feed, sleep, and be consoled, and reduce potential complications.

   Important medical note: Medications used to treat this syndrome must be administered under the supervision of a neonatologist in a hospital setting. Dosages are determined according to the infant’s weight, clinical condition, and response to treatment. Close monitoring is required because of potential adverse effects, including respiratory depression.

   First: Medications Used in Treatment

   1. Morphine

   Morphine is one of the commonly used medications for treating moderate to severe withdrawal symptoms resulting from prenatal opioid exposure.

   • Helps relieve severe irritability, crying, tremors, and feeding difficulties associated with withdrawal.

   • Is usually administered orally according to the approved medical protocol.

   • The dosage is gradually adjusted based on the infant’s response and symptom severity.

   • Requires monitoring of breathing, level of alertness, and feeding throughout treatment.

   2. Methadone

   Methadone is used as an alternative to morphine in some hospital protocols for treating opioid-related withdrawal symptoms.

   • Its long duration of action may help control symptoms.

   • Requires careful dose determination and monitoring of the newborn’s response.

   • Its prolonged effects require attention to the possibility of drug accumulation, drowsiness, and respiratory depression.

   3. Clonidine

   Clonidine may be used as an adjunctive medication when symptoms are not adequately controlled with initial treatment alone.

   • Helps reduce the excessive sympathetic nervous system activity associated with withdrawal.

   • May be added to morphine or methadone in selected cases.

   • Requires monitoring of blood pressure and heart rate.

   • Must be tapered according to an appropriate medical plan to avoid adverse effects associated with abrupt discontinuation.

   4. Phenobarbital

   Phenobarbital may be used as an adjunctive medication in certain cases, particularly when exposure to multiple substances has occurred or symptoms persist despite initial treatment.

   • Helps control certain neurological symptoms and may be used in specific cases based on the physician’s assessment.

   • May cause drowsiness and lethargy.

   • Can affect breastfeeding or feeding effectiveness in the infant.

   • Requires close monitoring because of its sedative effects and potential to cause respiratory depression.

   Second: How Is the Appropriate Treatment Selected?

   Treatment selection depends on symptom severity, the infant’s ability to feed, sleep, and be consoled, and the response to initial supportive care.

   Severity of the condition	Typical management approach
   Mild symptoms	Supportive care and medical monitoring
   Moderate to severe symptoms	An opioid medication, such as morphine or methadone, may be used according to the approved protocol
   Persistent symptoms despite treatment	Reassessment of the infant’s condition and dosage, with consideration of adding an adjunctive medication in selected cases

   Third: The Importance of Non-Pharmacological Care

   Non-pharmacological care is an essential component of NAS management, whether or not the infant requires medication.

   Key supportive measures include:

   • Providing a calm environment with reduced lighting and noise.

   • Holding, soothing, and safely swaddling the infant.

   • Offering small, frequent feeds according to the infant’s needs.

   • Supporting breastfeeding when medically appropriate, after assessing the medications and substances used by the mother.

   • Monitoring weight, hydration, breathing, and sleep.

   • Encouraging rooming-in and keeping the mother and infant together when their medical conditions permit.

   Fourth: When Should Medication Be Reduced or Discontinued?

   Once the infant’s condition stabilizes and feeding, sleeping, and consolability improve, the healthcare team determines when to begin gradually reducing medication dosages according to the established protocol and the newborn’s response.

   Medications should not be stopped abruptly or adjusted without medical supervision, as this may lead to the recurrence of withdrawal symptoms or other effects associated with discontinuation.

   Prevention and Care Tips for Neonatal Abstinence Syndrome (NAS)

   Prevention and early intervention are among the most important strategies for reducing complications associated with Neonatal Abstinence Syndrome. Management depends on appropriate maternal healthcare during pregnancy, medical monitoring of the newborn after birth, and adequate support for the family.

   First: Tips for Preventing Neonatal Abstinence Syndrome

   1. Attend Regular Prenatal Appointments

   Attend routine prenatal checkups and inform the healthcare provider about all medications and substances the mother uses. This helps assess potential risks and determine appropriate treatment for both mother and baby.

   2. Use Medications Safely

   Avoid taking medications without medical advice. Do not abruptly discontinue prescribed medications, particularly opioids or psychiatric medications, without medical supervision.

   3. Seek Specialized Treatment When Needed

   Early medical assistance should be sought if a substance use disorder is present. The healthcare provider may recommend specialized treatment, including medication when appropriate, rather than abrupt discontinuation, which may pose risks to both the mother and fetus.

   4. Avoid Smoking, Alcohol, and Harmful Substances

   Avoid smoking, alcohol, and illicit substances during pregnancy. Seek professional support to stop using these substances safely and effectively.

   5. Plan for Newborn Monitoring After Birth

   Inform the maternity care team about any potential medication or substance exposure during pregnancy so they can determine whether the newborn requires monitoring and establish an appropriate observation period.

   Second: Caring for a Newborn with NAS

   1. Provide a Calm and Comfortable Environment

   • Reduce surrounding light and noise.

   • Avoid unnecessary handling and excessive stimulation.

   • Hold and soothe the infant gently while ensuring safety and meeting the baby’s needs.

   2. Pay Attention to Feeding

   • Offer small, frequent feeds according to the infant’s needs and the healthcare team’s recommendations.

   • Monitor the infant’s sucking and swallowing abilities.

   • Track weight and the number of wet diapers.

   • Consult a healthcare professional about breastfeeding and its suitability based on the mother’s medications and health status.

   3. Follow Safe Sleep Guidelines

   • Always place the infant on their back to sleep.

   • Use a firm, flat sleep surface.

   • Keep the infant’s crib free of pillows, toys, and loose bedding.

   • Avoid sleeping with the infant on an adult’s chest if there is any possibility of falling asleep.

   4. Follow Medical Monitoring Recommendations

   Monitor symptoms such as tremors, irritability, excessive crying, feeding difficulties, and sleep disturbances. Inform the healthcare team of any noticeable changes in the infant’s condition.

   5. Follow the Treatment and Follow-Up Plan

   Administer medications only as directed by the physician. Do not change dosages or discontinue treatment without medical advice, and attend all recommended follow-up appointments after hospital discharge.

   Third: Warning Signs That Require Immediate Medical Attention

   Seek immediate medical assistance if any of the following signs occur:

   • Difficulty breathing or bluish discoloration of the lips.

   • Seizures.

   • Extreme lethargy or difficulty waking the infant.

   • Inability to feed or signs of dehydration.

   • Elevated body temperature or deterioration in the infant’s overall condition.

   These symptoms should not automatically be attributed to Neonatal Abstinence Syndrome alone, as they may indicate other serious medical conditions in newborns.

   Fourth: Important Advice for Families

   • Provide emotional support to the mother and avoid blame or stigma.

   • Learn techniques for soothing the infant and recognizing signs of hunger and distress.

   • Do not give the newborn herbal remedies or home medications without consulting a healthcare professional.

   • Seek assistance from the healthcare team when experiencing feeding difficulties or challenges soothing the infant.

   • Ensure that a clear care and follow-up plan is in place before hospital discharge.